WO2006135925A3 - Methods to reduce oxalate concentration by administration of oxalate oxidase crystals - Google Patents

Methods to reduce oxalate concentration by administration of oxalate oxidase crystals Download PDF

Info

Publication number
WO2006135925A3
WO2006135925A3 PCT/US2006/023115 US2006023115W WO2006135925A3 WO 2006135925 A3 WO2006135925 A3 WO 2006135925A3 US 2006023115 W US2006023115 W US 2006023115W WO 2006135925 A3 WO2006135925 A3 WO 2006135925A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxalate
crystals
administration
methods
concentration
Prior art date
Application number
PCT/US2006/023115
Other languages
French (fr)
Other versions
WO2006135925A2 (en
Inventor
Bhami C Shenoy
Mark X Yang
Margaret A Mcgrath
Alex L Margolin
Original Assignee
Bhami C Shenoy
Mark X Yang
Margaret A Mcgrath
Alex L Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bhami C Shenoy, Mark X Yang, Margaret A Mcgrath, Alex L Margolin filed Critical Bhami C Shenoy
Priority to JP2008516040A priority Critical patent/JP5199077B2/en
Priority to CA2610159A priority patent/CA2610159C/en
Priority to AU2006257787A priority patent/AU2006257787A1/en
Priority to US11/916,858 priority patent/US20080311101A1/en
Priority to EP06773127A priority patent/EP1928551B1/en
Publication of WO2006135925A2 publication Critical patent/WO2006135925A2/en
Publication of WO2006135925A3 publication Critical patent/WO2006135925A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to methods to prevent, treat, or slow the progression of a disorder associated with elevated oxalate concentration, the method comprising administering oxalate oxidase crystals, cross-linked crystals, or compositions containing those crystals to an individual. Oxalate oxidase crystals and compositions for administration to an individual are also provided, including stabilized crystals, such as cross-linked crystals of oxalate oxidase.
PCT/US2006/023115 2005-06-10 2006-06-12 Methods to reduce oxalate concentration by administration of oxalate oxidase crystals WO2006135925A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2008516040A JP5199077B2 (en) 2005-06-10 2006-06-12 Method for reducing oxalate concentration by administration of oxalate oxidase crystals
CA2610159A CA2610159C (en) 2005-06-10 2006-06-12 Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
AU2006257787A AU2006257787A1 (en) 2005-06-10 2006-06-12 Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
US11/916,858 US20080311101A1 (en) 2005-06-10 2006-06-12 Method to Reduce Oxalate Concentration by Administration of Oxalate Oxidase Crystals
EP06773127A EP1928551B1 (en) 2005-06-10 2006-06-12 Methods to reduce oxalate concentration by administration of oxalate oxidase crystals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68946805P 2005-06-10 2005-06-10
US60/689,468 2005-06-10

Publications (2)

Publication Number Publication Date
WO2006135925A2 WO2006135925A2 (en) 2006-12-21
WO2006135925A3 true WO2006135925A3 (en) 2007-03-29

Family

ID=37102997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/023115 WO2006135925A2 (en) 2005-06-10 2006-06-12 Methods to reduce oxalate concentration by administration of oxalate oxidase crystals

Country Status (6)

Country Link
US (1) US20080311101A1 (en)
EP (2) EP2465579A1 (en)
JP (1) JP5199077B2 (en)
AU (1) AU2006257787A1 (en)
CA (1) CA2610159C (en)
WO (1) WO2006135925A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103272225B (en) 2006-08-02 2018-05-22 味之素阿尔西亚有限公司 The oxalate decarboxylase and application method of crystallization
US9714456B2 (en) 2013-01-18 2017-07-25 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
CA2913476A1 (en) 2013-06-07 2014-12-11 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
WO2015097148A1 (en) * 2013-12-23 2015-07-02 Nexttobe Ab Method for producing oxalate oxidases having activity optimum near physiological ph and use of such recombinant oxalate oxidases in the treatment of oxalate-related diseases
US11603524B2 (en) 2015-04-02 2023-03-14 Oxidien Pharmaceuticals, Llc High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
CN107868776A (en) 2016-09-23 2018-04-03 武汉康复得生物科技股份有限公司 Glycosylate oxalate decarboxylase and its preparation and application
US20210363506A1 (en) * 2018-05-08 2021-11-25 Yale University Compositions And Methods For Reducing Progression Of Nephrolithiasis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011001A (en) * 1990-08-03 2000-01-04 Vertex Pharmaceuticals, Inc. Method of protein therapy by orally administering crosslinked protein crystals
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756090A (en) 1991-02-21 1998-05-26 Eoe, Inc. Oxygen activatable formulations for disinfection or sterilization
ES2152225T3 (en) 1991-02-25 2001-02-01 Zeneca Ltd USE OF A GENE THAT CODIFIES OXALATE-OXIDASE FOR THE TRANSFORMATION OF PLANTS.
US6229065B1 (en) 1991-03-05 2001-05-08 Rhone-Poulenc Agrochimie Production of plants resistant to attacks by Sclerotinia sclerotiorum by the introduction of a gene encoding an oxalate oxidase
EP0525723B1 (en) 1991-07-29 1997-05-14 Mochida Pharmaceutical Co., Ltd. Process and device for specific binding assay
DK0661989T3 (en) * 1992-09-21 1998-03-02 Upjohn Co Prolonged release protein compositions
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US6355242B1 (en) 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
KR20010012845A (en) 1997-05-23 2001-02-26 아익션 바이오테크놀로지, 인코퍼레이티드 Oxalate-degrading microorganisms or oxalate-degrading enzymes for preventing oxalate-related disease
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP4965022B2 (en) * 1998-04-27 2012-07-04 アルタス ファーマシューティカルズ インコーポレイテッド Stabilized protein crystals, formulations containing the same, and methods of making the same
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011001A (en) * 1990-08-03 2000-01-04 Vertex Pharmaceuticals, Inc. Method of protein therapy by orally administering crosslinked protein crystals
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PUNDIR C S ET AL: "ISOLATION, PURIFICATION, IMMOBILIZATION OF OXALATE OXIDASE AND ITS CLINICAL APPLICATIONS", HINDUSTAN ANTIBIOTICS BULLETIN, vol. 35, no. 1/2, February 1993 (1993-02-01), pages 173 - 182, XP002044102, ISSN: 0018-1935 *
RAMAKRISHNAN V ET AL: "INVESTIGATION WITH CHITOSAN-OXALATE OXIDASE-CATALASE CONJUGATE FOR DEGRADING OXALATE FROM HYPEROXALURIC RAT CHYME", INDIAN JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS, COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH, NEW DEHLI, IN, vol. 34, no. 4, August 1997 (1997-08-01), pages 373 - 378, XP008065786, ISSN: 0301-1208 *
SVEDRUZIC D ET AL: "The enzymes of oxalate metabolism: unexpected structures and mechanisms", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, US, vol. 433, no. 1, 1 January 2005 (2005-01-01), pages 176 - 192, XP004665470, ISSN: 0003-9861 *
WOO E-J ET AL: "Barley oxalate oxidase is a hexameric protein related to seed storage proteins: evidence from X-ray crystallography", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 437, no. 1-2, 16 October 1998 (1998-10-16), pages 87 - 90, XP004258496, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
CA2610159C (en) 2015-03-31
JP5199077B2 (en) 2013-05-15
JP2009501136A (en) 2009-01-15
US20080311101A1 (en) 2008-12-18
EP2465579A1 (en) 2012-06-20
AU2006257787A1 (en) 2006-12-21
EP1928551A2 (en) 2008-06-11
CA2610159A1 (en) 2006-12-21
EP1928551B1 (en) 2012-05-30
WO2006135925A2 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
WO2008105911A3 (en) Crystallized oxalate decarboxylase and methods of use
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
WO2006037024A3 (en) Salts of decitabine
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006034154A3 (en) Salts of 5-azacytidine
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
WO2003096983A3 (en) Method of treating dyslipidemic disorders
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2006135925A3 (en) Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
WO2007094819A3 (en) Triazole compounds that modulate hsp90 activity
WO2005012243A3 (en) Substituted indole-o-glucosides
WO2006086562A3 (en) Phenylazetidinone derivatives
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
WO2006091395A3 (en) Inhibitors of akt activity
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2007139955A8 (en) Triazole compounds that modulate hsp90 activity
WO2007139968A3 (en) Triazole compounds that modulate hsp90 activity
WO2008024302A3 (en) Compounds for treating proliferative disorders
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
WO2006110638A3 (en) Inhibitors of akt activity
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2006080549A3 (en) Method and composition for treating central nervous system disorders

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2610159

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006773127

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006257787

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008516040

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006257787

Country of ref document: AU

Date of ref document: 20060612

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06773127

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11916858

Country of ref document: US